60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.
60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.
Price: 1.17, Change: -0.10, Percent Change: -7.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.